NCT06109779 2026-03-04
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
AstraZeneca
Phase 3 Active not recruiting
Clinical Trials
10 trialsNCT04430738 2026-02-24
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Phase 2 Active not recruiting
NCT07328919 2026-01-09
Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations
TransThera Sciences (Nanjing), Inc.
Phase 3 Not yet recruiting
NCT07296666 2025-12-22
Adjuvant Chemotherapy for BTC Based on 3D-PTA
Fudan University
Phase 2 Not yet recruiting
NCT03929666 2025-09-12
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Phase 2 Completed
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT06406816 2025-05-15
Neoantigen Vaccine Plus Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma After Radical Resection
Meng Chao Hepatobiliary Hospital of Fujian Medical University
Phase EARLY_PHASE1 Recruiting
NCT05239169 2025-05-01
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT06622057 2025-04-30
D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
InnoPharmax Inc.
Phase 3 Not yet recruiting
NCT02170090 2025-03-30
ACTICCA-1
Universitätsklinikum Hamburg-Eppendorf
Phase 3 Active not recruiting